Based on 5 Wall Street analysts who have issued ratings for Ovid Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 5 analysts, 4 have given a buy rating, and 1 has given a strong buy rating for OVID.
According to the 5 analysts' twelve-month price targets for Ovid Therapeutics, the average price target is $3.13. The highest price target for OVID is $4.00, while the lowest price target for OVID is $1.50. The average price target represents a forecasted upside of 412.30% from the current price of $0.61.
Price Target Based on short-term price targets offered by four analysts, the average price target for Ovid Therapeutics comes to $2.88. The forecasts range from a low of $1.50 to a high of $4.00. The average price target represents an increase of 423.64% from the last closing price of $0.55.
Broker Rating Ovid Therapeutics currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, six are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Market Data 
Markets 
AI
